Since our founding, we have been working at the forefront of healthcare to bring innovative solutions to people who need them most. We developed and commercialised a treatment option for patients with hallucinations and delusions associated with Parkinson's disease psychosis in the United States, as well as another treatment option for patients with Rett syndrome in the United States and Canada. We are working to seek approval of our treatment option for people living with Rett syndrome in Europe.
Our Focus
Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programmes targeting neuropsychiatric symptoms in central nervous system disorders.
